Sarepta Therapeutics Inc. (SRPT) Upgraded to Hold by Jefferies Group
Sarepta Therapeutics Inc. (NASDAQ:SRPT) was upgraded by stock analysts at Jefferies Group from an “underperform” rating to a “hold” rating in a research note issued on Monday. The brokerage presently has a $50.00 price objective on the stock. Jefferies Group’s price target indicates a potential downside of 10.28% from the company’s previous close.
Other analysts have also recently issued reports about the stock. Piper Jaffray Cos. restated a “sell” rating and issued a $6.00 price target on shares of Sarepta Therapeutics in a report on Saturday, June 4th. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research note on Sunday, July 17th. Wedbush reiterated a “neutral” rating and issued a $14.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, May 25th. SunTrust Banks Inc. reiterated a “reduce” rating on shares of Sarepta Therapeutics in a research note on Friday, May 27th. Finally, William Blair upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 target price for the company in a research note on Monday. Two analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $51.01.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 55.73 on Monday. The company’s market capitalization is $2.67 billion. The firm has a 50 day moving average of $28.17 and a 200-day moving average of $21.37. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $56.80.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter last year, the company posted ($0.87) EPS. Equities analysts expect that Sarepta Therapeutics will post ($4.98) EPS for the current year.
In other news, CEO Edward M. Md Kaye sold 24,557 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 10.90% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Teacher Retirement System of Texas raised its position in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. bought a new stake in Sarepta Therapeutics during the second quarter worth about $154,000. Quantitative Systematic Strategies LLC bought a new stake in Sarepta Therapeutics during the second quarter worth about $211,000. National Planning Corp boosted its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares in the last quarter. Finally, First Allied Advisory Services Inc. boosted its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares in the last quarter. 72.09% of the stock is owned by hedge funds and other institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.